| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | BRD-K44224150 | CTRPv2 | pan-cancer | AAC | -0.043 | 0.6 |
| mRNA | UNC0321 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | BRD-K30019337 | CTRPv2 | pan-cancer | AAC | -0.039 | 0.6 |
| mRNA | BRD-K27188169 | CTRPv2 | pan-cancer | AAC | 0.029 | 0.6 |
| mRNA | GDC-0941 | gCSI | pan-cancer | AAC | 0.034 | 0.6 |
| mRNA | SR-II-138A | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.032 | 0.6 |